Olaparib for high-risk, early-stage breast cancer approved in Europe 04 Aug 2022 The Institute of Cancer Research, London, strongly welcomes the news that the precision medicine olaparib has been approved in Europe for people with high-risk, early-stage breast cancer who have inherited faults in their BRCA1 or BRCA2 genes. Find out more Show/Hide
Pioneering ICR scientist wins prestigious translational cancer research award 06 Jul 2022 Dr George Poulogiannis, leader of the Signalling and Cancer Metabolism Team at The Institute of Cancer Research, London, has received the 2022 British Association of Cancer Research–AstraZeneca Young Scientist Frank Rose Award for his research into the role of metabolism and nutrition in cancer development and therapy response. Find out more Show/Hide
EMA recommends olaparib for treatment of high-risk, early breast cancer 27 Jun 2022 The Institute of Cancer Research, London, strongly welcomes the news that olaparib has been recommended by the European Medicines Agency (EMA) to treat people with high-risk, early-stage breast cancer who have inherited faults in their BRCA1 or BRCA2 genes. Find out more Show/Hide
AACR 2022: Team of scientists and clinicians wins global award for transforming breast cancer treatment 04 Apr 2022
Study shows more women with invasive lobular breast cancer should qualify for tailored clinical trials 30 Mar 2022
Longer course of hormonal therapy before surgery for breast cancer has greater impact on tumour growth 23 Mar 2022
ESMO Virtual Plenary 2022: Major trial shows targeted drug improves survival in early-stage breast cancer with inherited BRCA1 or BRCA2 mutation 16 Mar 2022
Liquid biopsies one step closer to entering the clinic to help guide breast cancer treatment 01 Nov 2021